|Music to our ears ???|
Why 2018 is a make-or-break year for pharma
By Emma Court
Published: Jan 3, 2018 3:15 p.m. ET
Many drugmakers have neglected their pipelines, and will look to acquisitions to bolster them, one expert said
This year looks — at least on paper — like an unprecedentedly good setup for the pharmaceutical industry.
But behind the scientific breakthroughs, a Food and Drug Administration churning out approvals and drug-price regulation never materializing, the industry appears shockingly fragile.
Some of drugmakers’ most profitable products are aging, or simply old — nearly two decades old, in some cases — and staring down new competition.
Meanwhile, many big companies’ pipelines, typically a source of new development and the next billion-dollar drugs, are dry.
Acquisitions will thus become an integral part of the path foward, industry observers say, especially after a year of underwhelming merger-and-acquisition activity.